Grape Seed Powder and Vitamin C Supplementation for Liver Disease (Acquired Hepatic Jaundice) (AHJ)

May 7, 2026 updated by: Aleena Zahid, University of Lahore Hospital (ULH)

Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice

Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week).

According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan
        • University of Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Both men and women
  • Participants between the ages of 20-40 years will be included
  • Patients having signs and symptoms of acquired hepatic jaundice
  • Patients having high serum bilirubin, albumin, ALT, AST, ALP levels
  • The patient having ALT level more than 10-50 U/L were included
  • The participants having AST level above than 0-40 IU/L were included in this study
  • Patients having ALP level more than 30 - 130 U/L were included in this research study
  • Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation
  • Participants having the range of albumin more than 30-50 g/L were included in this research
  • Participants those were underweighted were included

Exclusion Criteria:

  • Patients who already taking any supplement or medication
  • Participants taking any anti-inflammatory medications
  • People who were suffering from any other disease
  • Patients who have any known allergies
  • Non willing patients
  • Lactating women
  • Pregnant women
  • Smokers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Conventional group
Control group
Experimental: Intervention group
Targeted group with intervention
Dietary supplement: Grape-C supplement
Grape-C supplement purchased from Nutrifactor brand.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bilirubin levels
Time Frame: 4 weeks
In this study results showed the significant decrease in bilirubin levels in interventional group as compared to the conventional group
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore Hospital (ULH)

Investigators

  • Study Chair: Dr Habib-ur-Rehman Rehman, PhD Food and Nutrition, University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • DOI: 10.4103/1319-3767.65197

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2023

Primary Completion (Actual)

March 17, 2023

Study Completion (Actual)

April 4, 2023

Study Registration Dates

First Submitted

May 4, 2026

First Submitted That Met QC Criteria

May 4, 2026

First Posted (Actual)

May 8, 2026

Study Record Updates

Last Update Posted (Actual)

May 12, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AZ786
  • University of Lahore (Other Identifier: Self)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Jaundice

Clinical Trials on Grape-C supplement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe